How licensing agreements can save lives in low- and middle income countries

Recent Developments in licensing In July 2022, ViiV Healthcare, the manufacturer of cabotegravir, signed a voluntary licensing agreement with the Medicines Patent Pool (MPP). This agreement allows generic manufacturers to produce and supply cabotegravir in 90 low- and middle-income countries. Continue reading How licensing agreements can save lives in low- and middle income countries

More Oligonucleotide Drugs Approved

Oligonucleotide drugs, also known as antisense drugs, are a type of medication designed to target specific genes in order to treat or prevent diseases. They work by binding to messenger RNA (mRNA) molecules and blocking their ability to produce certain Continue reading More Oligonucleotide Drugs Approved

Nusinersen API

Nusinersen is an oligonucleotide drug approved by the FDA in 2016 for the treatment of spinal muscular atrophy (SMA). SMA is a rare genetic disease that affects the muscles used for movement, breathing, and swallowing. Nusinersen is the first and Continue reading Nusinersen API